Assessment of quality of life (QoL) is now firmly established as an important endpoint in our evaluation of new treatments and interventions. An ever-increasing number of trials and studies report QoL as an outcome, in patients with nonmalignant and malignant chronic diseases of the pancreas. The emergence of this approach to pancreatic disease has been an important move forward where there has been previously little consideration of the impact of these diseases and their treatment from the patients’ perspective.